TrovaGene Stock Rating Reaffirmed by Aegis (TROV)
TrovaGene (NASDAQ:TROV)‘s stock had its “buy” rating restated by equities research analysts at Aegis in a research note issued to investors on Tuesday, American Banking & Market News reports. They currently have a $14.00 target price on the stock. Aegis’ target price points to a potential upside of 94.99% from the stock’s previous close.
Separately, analysts at Cantor Fitzgerald initiated coverage on shares of TrovaGene (NASDAQ:TROV) in a research note to investors on Monday, July 15th. They set a “buy” rating and a $10.00 price target on the stock.
Shares of TrovaGene (NASDAQ:TROV) traded up 13.29% on Tuesday, hitting $8.1339. 371,301 shares of the company’s stock traded hands. TrovaGene has a one year low of $3.35 and a one year high of $10.27. The stock has a 50-day moving average of $7.87 and a 200-day moving average of $7.00. The company’s market cap is $153.3 million.
TrovaGene (NASDAQ:TROV) last released its earnings data on Wednesday, August 14th. The company reported ($0.34) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.19. On average, analysts predict that TrovaGene will post $-0.84 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.